Navigation Links
Sleeping sickness drug may provide long-term protection against skin cancer
Date:10/23/2011

BOSTON An antiparasitic agent used to treat African sleeping sickness might someday be used to prevent nonmelanoma skin cancers. Researchers found that DFMO, or α-difluoromethylornithine, still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug, according to a poster presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.

In this follow-up study, researchers evaluated prolonged evidence of a protective effect of DFMO among 209 people who had participated in an earlier study. The researchers also wanted to ensure there were no obvious deleterious effects associated with the drug, according to Howard H. Bailey, M.D., professor of medicine, and study presenter Sarah Lamont, a medical student, both from the University of Wisconsin School of Medicine and Public Health.

The original study was a phase III, randomized, double-blind, prospective study of 291 men and women with a history of nonmelanoma skin cancer. They were assigned to either DFMO or a placebo for four to five years. At the end of the study period, researchers found a reduced skin cancer incidence among those assigned to DFMO.

"We showed a significant protective effect against basal cell carcinoma, but not a significant amount of protection against squamous cell carcinoma of the skin," Bailey said.

The main side effect was a slight ototoxicity that was found on testing, but this was not associated with a noticeable reduction in hearing by the subjects.

In the current retrospective study, researchers reviewed the electronic medical records of 209 of the original participants to establish cancer rates and to see if any other illnesses they might have developed could be attributed to DFMO.

"We found there is still evidence that the men and women assigned to DFMO for five years continued to have a lower incidence of nonmelanoma skin cancers compared with people assigned to placebo," Bailey said. "What we saw was that the presumed benefit that people got in taking DFMO appeared to persist for years after stopping it."

Study limitations include that participants may have been followed differently or changed their behaviors to limit sun exposure because of being in the original study, Bailey said.

"Our data suggest that the protective event that we saw in our prospective study appears to continue and there was no evidence of any rebound effect," he said. "We did not find any evidence that the people who received DFMO were harmed [other than the original ototoxicity]."

However, Bailey cautioned, more studies are needed before DFMO can be recommended as a prophylaxis against nonmelanoma skin cancers.

He added that such prophylaxis measures are needed because public health efforts to teach people about limiting sun exposure have not resulted in fewer cases of skin cancer, with more than 2 million cases of nonmelanoma skin cancer diagnosed each year. "The incidence continues to rise despite public health efforts to get people to lessen their sun exposure," Bailey said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Sometimes Sleeping on the Job May Be a Good Thing
2. Cautionary tale for people with diabetes: Dog consumed part of a sleeping patients toe
3. Could Sleeping on Left Side Help Prevent Stillbirth?
4. Sleeping through danger: the dormouse approach to survival
5. Scientists seek urgent treatment for fatal sleeping sickness
6. Most Babies Start Sleeping Through Night at 2 to 4 Months
7. Our children arent sleeping and were medicating them
8. Sleeping well at 100 years of age: Study searches for the secrets to healthy longevity
9. National Sleep Awareness Week(R) (March 7-13): How Are You Sleeping?
10. Bed Bug Insecticides Causing Sickness, Officials Warn
11. Going Full-Tilt Into Turns May Ease Motion Sickness on Trains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Donna Parker, L. ... she has not found any of them to be very practical. She wanted to ... and easily make changes in their health. It prompted her in writing “ A ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Learning to Use ... navigate life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is ... various nonprofits, former Chairman of the Board of Directors for CONTACT USA, and former ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: